Valiant Laboratories Full Year 2024 Earnings: EPS: ₹0.084 (vs ₹8.91 in FY 2023)

Valiant Laboratories (NSE:VALIANTLAB) Full Year 2024 Results

Key Financial Results

• Revenue: ₹1.82b (down 46% from FY 2023).
• Net income: ₹3.20m (down 99% from FY 2023).
• Profit margin: 0.2% (down from 8.7% in FY 2023).
• EPS: ₹0.084 (down from ₹8.91 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the India segment contributing a total revenue of ₹1.81b (99% of total revenue). Notably, cost of sales worth ₹1.70b amounted to 94% of total revenue thereby underscoring the impact on earnings.Over the last 12 months, the company's earnings were enhanced by non-operating gains of ₹106.9m. Explore how VALIANTLAB's revenue and expenses shape its earnings.

Valiant Laboratories shares are down 6.4% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Valiant Laboratories (2 are a bit concerning!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com